Default: AIDS

ISSN: 0269-9370

Journal Home

Journal Guideline

AIDS Q1 Unclaimed

Lippincott Williams and Wilkins Ltd. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

AIDS is a journal indexed in SJR in Infectious Diseases and Immunology with an H index of 216. It has an SJR impact factor of 2,195 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,195.

AIDS focuses its scope in these topics and keywords: hiv, antiretroviral, patients, hivinfected, therapy, cell, infection, cd, virus, viral, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

AIDS

2,195

SJR Impact factor

216

H Index

323

Total Docs (Last Year)

1106

Total Docs (3 years)

5175

Total Refs

3458

Total Cites (3 years)

874

Citable Docs (3 years)

2,87

Cites/Doc (2 years)

16,02

Ref/Doc

Aims and Scope


hiv, antiretroviral, patients, hivinfected, therapy, cell, infection, cd, virus, viral, hepatitis, women, risk, suppression, pneumonia, agents, immunoglobulin, prevention, increased, levels, nonaids, tuberculosis, treatment, people, receiving, responses,



Best articles by citations

Efficacy and safety of combination therapy with interferon-a2b and ribavirin for chronic hepatitis C in HIV-infected patients

View more

Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patients

View more

Intracellular cytokines in the acute response to highly active antiretroviral therapy

View more

Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality

View more

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients

View more

Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack)

View more

Reversible renal failure caused by a microsporidian infection

View more

Predictive value of repeated measurements of CD4 lymphocyte counts on progression to AIDS

View more

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants

View more

Influenza immunization of HIV-1-infected patients does not increase HIV-1 viral load

View more

Maternal HIV infection is an important health determinant in non-HIV-infected infants

View more

Sir, Esophageal candidiasis and immunodeficiency associated with acute HIV infection

View more
SHOW MORE ARTICLES

Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim) therapy in patients with AIDS

View more

Failure to infect lower primate species with SIVcpz

View more

Sexual behaviour in a rural high HIV prevalence South African community

View more

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

View more

Isolation of Mycobacterium interjectum in an AIDS patient with diarrhea

View more

Sexual behaviours, perception of risk of HIV infection, and factors associated with attending HIV post-test counselling in Ethiopia

View more

Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival

View more

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients

View more

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

View more

Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy

View more

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance

View more

Comparison of eight commercial test kits for detecting anti-HIV antibodies in saliva specimens

View more

Comments

No comments ... Be the first to comment!

FAQS